UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08 2024 - 8:00AM
Business Wire
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced the grants of
inducement restricted stock units (“RSUs”) to 12 new employees in
connection with their employment with UroGen. These new team
members will support the ongoing commercialization of Jelmyto®
(mitomycin) for pyelocalyceal solution, UroGen’s first approved
product, and the continued development of the Company’s
pipeline.
Up to 35,000 ordinary shares of UroGen are issuable upon the
vesting and settlement of the RSUs. The RSUs will vest equally over
three years, with one-third of the underlying shares vesting each
year on the anniversary of the vesting date, subject in each case
to the employee’s continued service relationship with UroGen.
The RSUs are subject to the terms and conditions of UroGen’s
2019 Inducement Plan and RSU grant notice and agreement thereunder.
The RSUs were granted as an inducement material to each employee
entering into employment with UroGen in accordance with Nasdaq
listing Rule 5635(c)(4).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. UroGen’s
first commercial product Jelmyto® (mitomycin) for pyelocalyceal
solution, and investigational treatment UGN-102 (mitomycin) for
intravesical solution for patients with low-grade non-muscle
invasive bladder cancer, are designed to ablate tumors by
non-surgical means. UroGen is headquartered in Princeton, New
Jersey with operations in Israel. Visit www.urogen.com to learn
more or follow us on Twitter, @UroGenPharma.
Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen
Pharma Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240308154847/en/
INVESTOR CONTACT: Vincent Perrone
vincent.perrone@urogen.com (609) 460-3588
MEDIA CONTACT: Cindy Romano Cindy.romano@urogen.com (609)
460-3583
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
UroGen Pharma (NASDAQ:URGN)
Historical Stock Chart
From Aug 2023 to Aug 2024